STAT1 and heart failure: In this context, a recent study in murine models of HFpEF demonstrated that empagliflozin, an SGLT2 inhibitor recommended for the treatment of HFpEF, reduces oxidative stress by inhibiting pro-inflammatory signalling in the STAT1 signalling pathway [42], further studies being needed to determine the extent to which it can reduce the risk of developing this type of heart failure in patients with chronic proliferative neoplasms.